On July 13, 2026 Drug Farm reported the successful first closing of its $55 million Series D financing. The financing round was co-led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise, with participation from new investors Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing investors, including BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas, also participated in the round.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The proceeds from the financing will support the continued advancement of Drug Farm’s clinical and preclinical stage pipeline, accelerate global clinical development programs, strengthen regulatory activities across key markets, and further expand the company’s research and development capabilities.
"The successful completion of this financing represents an important milestone in Drug Farm’s mission to develop first-in-class drugs for the world. We are pleased to welcome our new investors while receiving continued support from our long-term shareholders, reflecting strong confidence in the company’s scientific innovation, development strategy, and long-term vision. We believe this financing positions Drug Farm to create significant value for patients, partners, and shareholders in the years ahead," said Dr. Tian Xu, Founder and Chairman of Drug Farm.
Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, added, "We are delighted to complete this financing and grateful for the continued confidence and support from our investors. We are proud that DF-003 is amongst the first drugs developed with AI and entering a Phase 3 trial. The investment provides additional resources to advance DF-003 through the completion of a pivotal trial in patients with ROSAH syndrome and clinical proof of concept in atherosclerotic cardiovascular disease. The funds will also be used to continue clinical development of DF-006 in patients with hepatitis B."
Dr. Tony Xu, Chief Operating Officer of Drug Farm, commented, "Powered by IDInVivo+ and MedChem5, our proprietary platforms combining genetics and artificial intelligence continues to discover and validate novel drug targets and rapidly advance multiple first-in-class candidates into the clinic. This financing will help us bring additional breakthrough therapies to patients with unmet needs in metabolic and autoimmune diseases."
(Press release, Drug Farm, JUL 13, 2026, View Source [SID1234669179])